Tranexamic Acid in Adherent Placenta (TAP)

Status Withdrawn

Clinical Trial Summary

The objective of this study is to investigate the effect of tranexamic acid (TXA) administration on the outcome of cesarean-hysterectomy in women with suspected Morbidly Adherent Placenta (MAP; placenta accreta, increta, percreta).

Clinical Trial Description

This trial is a randomized, double blind, placebo controlled trial to quantify the effects of the preoperative administration of tranexamic acid on estimated blood loss and blood product utilization in women undergoing cesarean-hysterectomy for suspected MAP. Subgroup analyses will be performed for laboratory results (coagulation studies, electrolytes, complete blood count), urine output, hemodynamic parameters, return to OR for continued bleeding, post-operative complications (thromboembolism, wound separation, infection, fever), and length of hospital stay. Eligible patients will be randomized to receive either TXA or placebo.

Women eligible for inclusion will be identified during their prenatal course or on admission to the hospital prior to surgery. They will be offered participation in the study after appropriate counseling regarding the equipoise regarding TXA and its use in pregnancy, and following a question and answer period they will be consented, and assigned a study number.

A randomization table will be generated by the Texas Children's Hospital Investigational Pharmacy, using balanced blocks of 8, and will maintain control of the randomization to ensure blinding of participants and the clinical investigators. Randomization will occur when an order for study medication will be sent on a paper requisition to the Texas Children's Hospital Investigational Pharmacy, and a randomization number will be assigned to correspond to the study number. Ideally, this order will be sumbitted 24h prior to scheduled surgery, but may be submitted for urgent cases by calling the Texas Children's Clinical Pharmacy, and delivering the paper requisition to the 7th Floor Main Pharmacy.

The Investigational Pharmacy will prepare study medication (Tranexamic acid I.V. or Normal saline as placebo) as determined by the randomization. The medication (whether study medication or placebo) will be packaged in identical syringes. Sealed, opaque envelopes will be available to the PI or an assigned designee to permit unblinding (linking randomization number and study number) only in the event of a clinical emergency involving a study partipant during times at which the Investigational Pharmacy is closed (nights, weekends, holidays).

Once a patient has been randomized, the outcome in hospital will be collected even if the study medication is interrupted or not actually given. ;

Study Design

Related Conditions & MeSH terms

Placenta Accreta

Clinical Trial Details

NCT number	NCT02329756
Study type	Interventional
Source	Baylor College of Medicine
Contact
Status	Withdrawn
Phase	Phase 3
Start date	December 2018
Completion date	December 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04579172` - Conservative Management of Morbidly Adherent Anterior Situated Placenta	N/A
Completed	`NCT04593303` - Internal Iliac Artery Ligation During Management of Placenta Accreta Spectrum	N/A
Recruiting	`NCT03638024` - Cell-free Fetal DNA Concentration in Cases of Abnormal Placental Invasion .
Not yet recruiting	`NCT06100640` - Paracervical Pouch in Placenta Accreta Spectrum
Completed	`NCT05979181` - Peripartum Cesarean Hysterectomy for Placenta Percreta
Recruiting	`NCT04609527` - Management of Placenta Accreta Spectrum	Phase 2/Phase 3
Recruiting	`NCT06185894` - Single-step Placenta Accreta Resective Technique Tourniqueted vs Absence, Conservative Uterine Surgery	N/A
Completed	`NCT04573452` - Galectin-3 and Placenta Accreta
Not yet recruiting	`NCT03273569` - PDIUC Protocol for Placental Accreta	N/A
Completed	`NCT03707132` - Tourniquet Reduces Blood Loss in Postpartum Hemorrhage During Hysterectomy for Placenta Accreta
Not yet recruiting	`NCT05104177` - Effectivness of Conservative Techniques in Management of PAS
Completed	`NCT02806024` - Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study	Phase 4
Active, not recruiting	`NCT02784886` - Cell-free Fetal DNA Circulating in the Maternal Plasma as a Marker for Morbidly Adherent Placenta	N/A
Recruiting	`NCT05070689` - Placenta Accreta Spectrum Disorders: A. Chohan Continuous Squeezing Suture (ACCSS)	N/A
Completed	`NCT05813743` - Detection of Urinary Bladder Wall Involvement in Abnormally Invasive Placenta (AIP) by 3D Ultrasonography	N/A
Withdrawn	`NCT04003428` - Feasibility of HIFU for Management of Placenta Accreta (HIFU-ACCRETA)	N/A
Completed	`NCT04161521` - Conservative Surgical Novel Technique of Placenta Accreta in Menoufia University Hospital	N/A
Recruiting	`NCT05139498` - Conservative Management for PAS Pilot	N/A
Not yet recruiting	`NCT03530475` - Diagnostic Accuracy of Doppler Ultrasound and Role of Uterine Artery Doppler	N/A
Recruiting	`NCT05922397` - Placenta Accreta Spectrum Topographic Classification

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.